Mass Torts

Strategic Comparison: Uber MDL vs Lyft, JUUL, Roundup, and the Boy Scouts/Catholic Church Precedent

MDL 3084 is not the first mass tort of its scale, and the comparables matter. Lyft is the parallel-defendant model. JUUL is the procedural blueprint. Roundup is the punitive-damages cautionary tale. The institutional-survivor cases are the adult-revival template. This is the business-of-law read on where MDL 3084 lands across all four, with per-case economics, framework timing, and firm-investment math.

Strategic Comparison: Uber MDL vs Lyft, JUUL, Roundup, and the Boy Scouts/Catholic Church Precedent

MDL 3084 is the first rideshare-platform sexual-assault MDL to reach a bellwether trial. It is not, however, the first mass tort of its scale or shape. Four earlier dockets — the Lyft sexual-assault MDL, the JUUL e-cigarette MDL, the Roundup glyphosate litigation, and the bankruptcy-driven survivor resolutions involving the Boy Scouts and the Catholic Church — sketch out the path MDL 3084 is most likely to follow. Each one lights up a different part of the picture: Lyft gives us the parallel-defendant comparison, JUUL the consumer-product corporate-conduct theory, Roundup the punitive-damages trajectory, and the institutional-survivor cases the adult-revival-window framework.

Who is this written for? The business-of-law reader. Managing partners weighing whether to commit firm resources to MDL 3084, finance teams modeling case-pipeline economics, and plaintiff steering committees calibrating their settlement-framework expectations against the historical comparables.

Lyft MDL — the closest parallel

Of the four, Lyft's sexual-assault MDL (MDL No. 2956, In re Lyft Driver Sexual Assault Litigation, also pending in the Northern District of California) is the closest factual match to MDL 3084. It was consolidated in 2020 and peaked at roughly 1,300 cases. Bellwether trials began in 2023, and the first major plaintiff verdict came in the 2024 Vivian v. Lyft trial, which returned approximately $20 million in compensatory damages.

Lyft's docket is much smaller than Uber's — about a third the case count — but that gap reflects market share, not a different underlying assault rate. It has also moved more slowly than the Uber MDL, largely because plaintiff firms front-loaded their resources on Uber. Lyft's case-management orders borrow heavily from MDL 3084's procedural framework, though the substantive law issues (non-delegable duty, common-carrier doctrine, Rule 404(b) admission of internal safety reports) were fought out more aggressively in Uber's docket and now apply to both.

Lyft has not yet entered global-settlement framework negotiation. The industry expectation is that its framework will trail Uber's by 12 to 18 months, scaled to case count. If Uber's framework values cases at an average of $700,000 net to plaintiff (consistent with the projections in the settlement framework analysis), Lyft's would plausibly land in the $400-700K range — a smaller total pool, but similar per-case math.

The strategic takeaway is straightforward. Plaintiff firms that already have Uber MDL infrastructure can extend the same intake, evidence, and settlement-framework expertise to Lyft cases for marginal additional cost. For plaintiff-side firms, the two MDLs are effectively one practice area. On the defense side, the two corporate defendants are coordinating their discovery posture more closely than the public docket lets on.

JUUL — the consumer-product mass-tort blueprint

The JUUL MDL (MDL No. 2913, In re JUUL Labs, Inc., Marketing, Sales Practices, and Products Liability Litigation) is not a factual parallel to MDL 3084. The underlying harm there is nicotine addiction and adolescent health damage, not sexual assault. What it offers instead is the procedural blueprint for consumer-product corporate-conduct litigation.

JUUL consolidated roughly 4,500 cases, plus thousands more in parallel state-court proceedings. Its settlement framework, announced in 2022 at approximately $1.7 billion globally across personal-injury and government claims, ran on a tier matrix with documented-harm adjustments. That framework is the template MDL 3084's PSC is most plausibly studying for its own tier structure.

Two lessons carry over. First, the framework took about four years from MDL consolidation to global settlement announcement. MDL 3084 was consolidated in October 2023, so if it tracks JUUL, framework negotiation lands in 2027. Second, JUUL's framework carried a substantial common-benefit assessment (around 10%) and resolved Medicare/Medicaid liens at favorable global terms — both features MDL 3084's framework is expected to replicate.

JUUL also built in an opt-out provision, which roughly 8% of plaintiffs used. Those plaintiffs proceeded individually, and most settled within the year on terms broadly in line with the framework tier they would otherwise have received. That opt-out rate is a useful planning anchor: expect about one in 12 plaintiffs to opt out, and keep individual-case capacity sized accordingly.

Roundup — the punitive-damages trajectory

The Roundup glyphosate litigation (spread across several state and federal proceedings, primarily MDL 2741) is the comparable for corporate conduct paired with punitive damages. The headline figures are enormous: Bayer's $11 billion global settlement framework, announced in 2020, followed by continued individual trials and supplementary settlements. Total Bayer exposure now runs past $16 billion.

For MDL 3084, the lesson worth borrowing from Roundup is the punitive-damages trajectory. Early Roundup bellwethers carried heavy punitive components — the Johnson, Hardeman, and Pilliod verdicts each included nine-figure punitive awards — and that punitive pressure is what brought Bayer to the framework table. Uber's first bellwether bifurcated punitives, and the parties settled the punitive phase. That move protects Uber's appellate flexibility, but it also leaves the punitive question hanging over the docket.

Here is where it gets consequential. Should a September 2026 bellwether take a punitive phase all the way to verdict and the jury hand back nine-figure punitives, the MDL 3084 settlement-framework valuation moves sharply upward. If instead Uber keeps bifurcating and settling punitives in every bellwether, the docket's compensatory-only valuation stays lower than it otherwise might. The punitive question is the wild card.

Roundup is also a reminder of how long a mass tort can tail off. Bayer's framework dates to 2020, yet individual trials and settlements were still happening in 2026. Plaintiff firms holding strong individual cases — especially ones with a strong punitive theory — can sometimes do better outside the framework than inside it. The cost is time and trial risk.

Boy Scouts and Catholic Church — the adult-survivor template

The Boy Scouts of America bankruptcy plan ($2.46 billion across approximately 82,000 abuse claims) and the various Catholic Church diocesan bankruptcies (cumulative liability exceeding $5 billion across multiple proceedings) are the closest template for adult-survivor mass resolution outside of bankruptcy. Both leaned on a tier-matrix approach, both relied on revival-window legislation to drive volume, and both produced average per-claim recoveries in the $20,000-$100,000 range — substantially lower than what MDL 3084 is expected to produce.

That recovery gap is worth understanding. Boy Scouts and Catholic Church claims paid out less, on average, for three reasons: the defendant entities held limited assets relative to claim count, which forced bankruptcy-driven pro rata distribution rather than negotiated per-case settlement; institutional plaintiffs' counsel coordinated aggressively to maximize claim count, which diluted per-case value; and the conduct timeline reached back decades, leaving weaker corroboration on individual cases.

MDL 3084 should land considerably higher. Uber's market capitalization — roughly $180 billion as of May 2026 — gives the defendant room to pay framework-level recovery without resorting to bankruptcy. The conduct timeline is shorter, with most relevant rides falling in the last 8-10 years, which strengthens corroboration. And plaintiffs' counsel is less concentrated than in the institutional cases, which has kept the dilution dynamic in check so far.

Where the institutional template matters most is the revival-window dynamic. Both proceedings drew enormous benefit from state-level revival legislation that reopened windows for older claims, and AB 2777 plays the same role for MDL 3084. The institutional cases also produced sophisticated, trauma-informed claim-evaluation processes that MDL 3084 is now drawing on for its tier-matrix damages assessment.

Where MDL 3084 lands relative to these comparables

Pull the four reference dockets together, and MDL 3084's most plausible settlement-framework profile comes into focus:

  • Total pool: $3-5 billion across approximately 4,000-5,000 claims (the current docket plus the filings expected through the 2027 framework deadline). The pool runs higher than JUUL's $1.7 billion because per-case severity is greater, and lower than Roundup's $11 billion because there are fewer claims and capped punitive exposure.
  • Per-case average: $700,000 gross / $400,000 net to plaintiff at framework conclusion. Well above the Boy Scouts / Catholic Church averages, comparable to upper-tier JUUL settlements, and below Roundup individual-trial outcomes.
  • Timing: framework negotiation in early-to-mid 2027, framework completion in 2028, and long-tail individual cases and appeals running through 2030 — roughly the JUUL timeline, scaled for the slightly larger docket.
  • Opt-out rate: 8-12% based on the JUUL precedent. Plaintiff firms should keep individual-case infrastructure sized to match.
  • Common-benefit assessment: 8-10% based on JUUL and Roundup precedent.
  • Lien resolution: a PSC-negotiated global resolution with CMS and the major Medicaid systems, parallel to the JUUL framework. ERISA lien resolution stays case-by-case, but improves under the aggregate posture.

Strategic implications for plaintiff firms

For plaintiff firms weighing an investment in MDL 3084 practice, three points matter.

The first is that the per-case economics justify real firm investment. At $400,000 net to plaintiff and a 40% contingency fee, gross attorney revenue per case runs roughly $300,000 to $600,000, depending on settlement tier. A firm carrying 50 to 100 cases in MDL 3084 plus parallel Lyft cases generates meaningful aggregate revenue against a per-case cost base of perhaps $15,000-$25,000 in pre-settlement expenses.

The second is that the practice infrastructure transfers. Firms with Uber MDL intake systems can repurpose them for Lyft, for any future rideshare MDL, and for parallel ground-transportation and hospitality-industry sexual-assault litigation. The upfront investment amortizes across a far longer horizon than any single MDL.

The third is timing, and it cuts against waiting. AB 2777's revival window expires December 31, 2026, and any case that depends on revival must be filed before that deadline. Firms that stand up MDL 3084 intake infrastructure in the back half of 2026 will capture the bulk of the revival-window-dependent cases; firms that arrive in 2027 or later face a substantially smaller addressable docket.

Strategic implications for Uber

For Uber, the comparables point to one dominant strategy: a framework settlement. Grinding on with bellwether litigation against well-resourced plaintiff firms armed with strong corporate-conduct evidence is unlikely to improve the company's position. The first two bellwethers established the floor (liability) without establishing a ceiling (damages), and every additional bellwether risks a Roundup-style punitive trajectory.

The likeliest path is framework negotiation in 2027, with a total pool sized to take tail risk off the table. That pool will be priced against the September 2026 bellwether verdicts: a strong plaintiff outcome drives it toward the top of the $3-5 billion range, while a defense-favorable outcome pulls it down. Either way, framework completion in 2027-2028 is the expected exit.

The publisher's read

Our read is that MDL 3084 will end up looking more like JUUL than Roundup — a sizable framework settlement reached within four years of MDL consolidation, tier-matrix per-case valuation in the seven-figure range, opt-out rates in the 8-12% band, and a multi-year individual-case tail. The defining variable is the punitive-damages trajectory: significant punitives out of the September bellwethers push valuation up toward Roundup territory, while successful bifurcation across the bellwether sequence keeps it in JUUL territory.

For the business-of-law reader, the bottom line is this: a major MDL with major investment economics, sitting at the leading edge of a brand-new mass-tort practice area in rideshare-platform sexual assault. Firms that build infrastructure here position themselves for a 10-year practice horizon across Uber, Lyft, and any future entrants. The window for new firm entry is roughly the next 12 to 18 months.

See also: MDL 3084 Hub Overview | Settlement Framework and Medical Liens | Bellwether Trial Tracker | Laws Affecting PI Rideshare Cases

The LawyersTrend Brief · Fridays

One weekly email. Every new article.

Friday mornings — every PI article we publish that week, plus rankings updates and key verdicts. Free. One-click unsubscribe.